IL13RA2 and neoplasm: They looked for IL13Ra2 presence in several carcinoma tissues and tested liposomal IL13-conjugated doxorubicin against glioblastoma tumors and in malignant peripheral nerve sheath tumors, demonstrating a decrease of tumor burden both in vitro and in vivo [108].